| IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy V Suppiah, M Moldovan, G Ahlenstiel, T Berg, M Weltman, ML Abate, ... Nature genetics 41 (10), 1100-1104, 2009 | 2385 | 2009 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1118 | 2019 |
| Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ... Gastroenterology 156 (6), 1717-1730, 2019 | 1050 | 2019 |
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation … PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ... The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020 | 576 | 2020 |
| Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis D Petroff, V Blank, PN Newsome, CS Voican, M Thiele, V de Lédinghen, ... The Lancet Gastroenterology & Hepatology 6 (3), 185-198, 2021 | 183 | 2021 |
| Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ... Nature communications 6 (1), 6422, 2015 | 181 | 2015 |
| Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised … D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ... The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017 | 171 | 2017 |
| Lipids and HCV MF Bassendine, DA Sheridan, SH Bridge, DJ Felmlee, RDG Neely Seminars in immunopathology 35, 87-100, 2013 | 139 | 2013 |
| IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study V Suppiah, S Gaudieri, NJ Armstrong, KS O'Connor, T Berg, M Weltman, ... PLoS medicine 8 (9), e1001092, 2011 | 135 | 2011 |
| MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C K Thabet, A Asimakopoulos, M Shojaei, M Romero-Gomez, A Mangia, ... Nature communications 7 (1), 12757, 2016 | 127 | 2016 |
| Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes M Eslam, A Mangia, T Berg, HLY Chan, WL Irving, GJ Dore, ML Abate, ... Hepatology 64 (1), 34-46, 2016 | 118 | 2016 |
| IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis M Eslam, D McLeod, KS Kelaeng, A Mangia, T Berg, K Thabet, WL Irving, ... Nature Genetics 49 (5), 795-800, 2017 | 103 | 2017 |
| FibroGENE: A gene-based model for staging liver fibrosis M Eslam, AM Hashem, M Romero-Gomez, T Berg, GJ Dore, A Mangia, ... Journal of hepatology 64 (2), 390-398, 2016 | 90 | 2016 |
| Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles DJ Felmlee, DA Sheridan, SH Bridge, SU Nielsen, RW Milne, CJ Packard, ... Gastroenterology 139 (5), 1774-1783. e6, 2010 | 82 | 2010 |
| HCV and the hepatic lipid pathway as a potential treatment target MF Bassendine, DA Sheridan, DJ Felmlee, SH Bridge, GL Toms, ... Journal of hepatology 55 (6), 1428-1440, 2011 | 78 | 2011 |
| GS-06-positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH Z Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... Journal of Hepatology 70 (1), e5, 2019 | 62 | 2019 |
| Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha … DA Sheridan, DA Price, ML Schmid, GL Toms, P Donaldson, D Neely, ... Alimentary pharmacology & therapeutics 29 (12), 1282-1290, 2009 | 55 | 2009 |
| IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection M Eslam, R Leung, M Romero-Gomez, A Mangia, WL Irving, D Sheridan, ... Journal of hepatology 61 (2), 235-241, 2014 | 50 | 2014 |
| Randomised clinical trial: palliative long‐term abdominal drains vs large‐volume paracentesis in refractory ascites due to cirrhosis L Macken, S Bremner, H Gage, M Touray, P Williams, D Crook, L Mason, ... Alimentary pharmacology & therapeutics 52 (1), 107-122, 2020 | 49 | 2020 |
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, ... Journal of hepatology 77 (2), 353-364, 2022 | 48 | 2022 |
Margaret BassendineVerified email at ncl.ac.uk